Cell Therapeutics to raise $6.5 million through private placement
Cell Therapeutics (CTI) will sell series D convertible preferred stock and warrants to investors at the negotiated price of $1,000 per share of series D convertible preferred stock.
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.